Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
- Journal:
- The Lancet Oncology
- Published:
- Affiliations:
- 35
- Authors:
- 40